Trial Profile
Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs TR 987 (Primary)
- Indications Wounds
- Focus Therapeutic Use
- Sponsors TR Therapeutics
- 16 May 2014 New trial record